2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.78 Faris Badin Abstract

Pdf Summary

The study, titled "First-line Nivolumab (N) Ipilimumab (I) Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update," provides an update on the efficacy and safety of this treatment regimen in patients with metastatic non-small cell lung cancer (mNSCLC). The authors conducted a randomized trial in which patients were assigned to receive either N and I in combination with C or C alone. The study found that N and I in combination with C provided durable overall survival (OS) benefit compared to C alone, with a hazard ratio of 0.74. This benefit was observed regardless of tumor PD-L1 expression or histology. The study also found that the discontinuation of N and I due to treatment-related adverse events did not negatively impact long-term outcomes. <br /><br />The 4-year minimum follow-up data showed that patients treated with N and I continued to experience long-term, durable efficacy compared to those treated with C alone. The overall response rate was higher in the N and I group, and the median duration of response was longer. The study did not identify any new safety signals with N and I treatment. <br /><br />These findings support the use of N and I in combination with C as a viable first-line treatment option for patients with mNSCLC, particularly those with high unmet needs, such as tumor PD-L1 expression of 1% or squamous histology. The study provides evidence for the long-lasting efficacy and safety of this treatment regimen in this patient population.

Asset Subtitle

Faris Badin

Keywords

Nivolumab

Ipilimumab

Chemotherapy

Metastatic NSCLC

CheckMate 9LA

Overall Survival

Tumor PD-L1 Expression

Histology

Treatment-related Adverse Events

Long-term Outcomes